Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone - PubMed (original) (raw)
Clinical Trial
. 1994 Nov 3;331(18):1188-93.
doi: 10.1056/NEJM199411033311803.
Affiliations
- PMID: 7935656
- DOI: 10.1056/NEJM199411033311803
Free article
Clinical Trial
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
J J Nolan et al. N Engl J Med. 1994.
Free article
Abstract
Background: Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known.
Methods: We performed oral and intravenous glucose-tolerance tests, studies with the euglycemic-hyperinsulinemic clamp, meal-tolerance tests, and 24-hour blood-pressure measurements at base line and after the administration of troglitazone, 200 mg orally twice daily, or placebo for 12 weeks in 18 nondiabetic obese subjects, 9 of whom had impaired glucose tolerance.
Results: The mean (+/- SD) rates of glucose disposal increased from 4.7 +/- 1.7 to 6.0 +/- 1.7 mg per kilogram of body weight per minute (P = 0.004) and from 9.0 +/- 1.8 to 9.9 +/- 1.3 mg per kilogram per minute (P = 0.02) during insulin infusions of 40 and 300 mU per square meter of body-surface area per minute, respectively, in the troglitazone group. The insulin-sensitivity index, calculated from the results of intravenous glucose-tolerance tests, increased from 0.7 +/- 0.6 x 10(-4) to 1.6 +/- 0.9 x 10(-4) in subjects given troglitazone, and their glycemic response to oral glucose and to mixed meals decreased. The mean fasting plasma insulin concentration decreased by 48 percent (P = 0.002), and the plasma insulin response to oral glucose and mixed meals decreased by 40 and 41 percent, respectively. The changes were similar in the subjects with normal glucose tolerance and those with impaired glucose tolerance. Systolic and diastolic blood pressure decreased by 5 +/- 2 mm Hg (P = 0.05) and 4 +/- 2 mm Hg (P = 0.04), respectively, after treatment with troglitazone. There were virtually no changes in the placebo group.
Conclusions: Troglitazone decreases insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance. The ability of troglitazone to reduce insulin resistance could be useful in preventing NIDDM:
Comment in
- Insulin resistance and the prevention of diabetes mellitus.
Keen H. Keen H. N Engl J Med. 1994 Nov 3;331(18):1226-7. doi: 10.1056/NEJM199411033311812. N Engl J Med. 1994. PMID: 7935664 No abstract available.
Similar articles
- Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Tack CJ, Ong MK, Lutterman JA, Smits P. Tack CJ, et al. Diabetologia. 1998 May;41(5):569-76. doi: 10.1007/s001250050948. Diabetologia. 1998. PMID: 9628275 Clinical Trial. - Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S, Prange A, Schulze J, Lettis S, Barnett AH. Kumar S, et al. Diabet Med. 1998 Sep;15(9):772-9. doi: 10.1002/(SICI)1096-9136(199809)15:9<772::AID-DIA677>3.0.CO;2-X. Diabet Med. 1998. PMID: 9737807 Clinical Trial. - Effects of troglitazone on insulin sensitivity.
Henry RR. Henry RR. Diabet Med. 1996 Sep;13(9 Suppl 6):S148-50. Diabet Med. 1996. PMID: 8894499 Review. - Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Inzucchi SE, et al. N Engl J Med. 1998 Mar 26;338(13):867-72. doi: 10.1056/NEJM199803263381303. N Engl J Med. 1998. PMID: 9516221 Clinical Trial. - The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC, Schneider EF, Fonseca VA. Granberry MC, et al. Pharmacotherapy. 1998 Sep-Oct;18(5):973-87. Pharmacotherapy. 1998. PMID: 9758309 Review.
Cited by
- Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation.
Lai YJ, Yeh YH, Huang YL, De Almeida C, Chang GJ, Chen WJ, Hsu HH. Lai YJ, et al. ACS Pharmacol Transl Sci. 2024 Aug 1;7(9):2725-2738. doi: 10.1021/acsptsci.4c00127. eCollection 2024 Sep 13. ACS Pharmacol Transl Sci. 2024. PMID: 39296270 - Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.
Rohm TV, Castellani Gomes Dos Reis F, Isaac R, Murphy C, Cunha E Rocha K, Bandyopadhyay G, Gao H, Libster AM, Zapata RC, Lee YS, Ying W, Miciano C, Wang A, Olefsky JM. Rohm TV, et al. Nat Metab. 2024 May;6(5):880-898. doi: 10.1038/s42255-024-01023-w. Epub 2024 Apr 11. Nat Metab. 2024. PMID: 38605183 - The Role of Selenium Nanoparticles in Addressing Diabetic Complications: A Comprehensive Study.
Satpathy S, Panigrahi LL, Arakha M. Satpathy S, et al. Curr Top Med Chem. 2024;24(15):1327-1342. doi: 10.2174/0115680266299494240326083936. Curr Top Med Chem. 2024. PMID: 38561614 Review. - Multi-Target Neuroprotection of Thiazolidinediones on Alzheimer's Disease via Neuroinflammation and Ferroptosis.
Yang J, Shi X, Wang Y, Ma M, Liu H, Wang J, Xu Z. Yang J, et al. J Alzheimers Dis. 2023;96(3):927-945. doi: 10.3233/JAD-230593. J Alzheimers Dis. 2023. PMID: 37927258 Free PMC article. Review. - Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study.
Qin C, Diaz-Gallo LM, Tang B, Wang Y, Nguyen TD, Harder A, Lu Y, Padyukov L, Askling J, Hägg S. Qin C, et al. Eur J Epidemiol. 2023 Jul;38(7):809-819. doi: 10.1007/s10654-023-01000-9. Epub 2023 Apr 13. Eur J Epidemiol. 2023. PMID: 37052755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials